Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin
These results support that patients experiencing any-grade cutaneous toxicity (skin rash) had a prolonged PFS. With the recent expansion of combined treatment using EV plus pembrolizumab in first-line in mUC patients, cutaneous toxicities need to be carefully monitored and optimized dedicated management provided, considering that cutaneous toxicity may be predictive of patient outcome.
Authors
- Aude Fléchon (ORCID: https://orcid.org/0000-0002-0129-6101)
- Sophie Tartas
- Helen Boyle (ORCID: https://orcid.org/0000-0002-8201-948X)
- Mona Amini‐Adlé (ORCID: https://orcid.org/0000-0003-2366-6238)
- Armelle Vinceneux
- F. Bérard
- Sylvie Chabaud (ORCID: https://orcid.org/0000-0003-4655-6867)
- Emmanuel Ribereau‐Gayon (ORCID: https://orcid.org/0000-0003-0054-0624)
- Sophie Darnis
- Benoît You (ORCID: https://orcid.org/0000-0002-3177-8857)
- Samy Belkaïd (ORCID: https://orcid.org/0000-0002-0350-1703)
- Gilles Freyer (ORCID: https://orcid.org/0000-0001-6001-164X)
- Julien Anriot (ORCID: https://orcid.org/0009-0006-9615-5438)
- Thibald Chalas
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Hospices Civils de Lyon (FR)
- Centre Léon Bérard (FR)
- Hôpital Lyon Sud (FR)
- HCL Technologies (India) (IN)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1016/j.ejca.2025.115427
- Citations
- 4
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.89